Literature DB >> 2378841

Ocular penetration of cyclosporin A. III: The human eye.

D BenEzra1, G Maftzir, C de Courten, P Timonen.   

Abstract

The distribution of cyclosporin A (CsA) in the blood, saliva, tears, aqueous humour, vitreous, and cerebrospinal fluid has been studied after oral treatment with 5 mg/kg/day of CsA or application of 2% CsA eye drops in olive oil solution. After oral treatment all patients had high CsA levels in blood. Measurable levels of CsA were also found in the saliva and tears. Patients without any intraocular inflammation or patients with mild uveitis did not have any detectable CsA in the aqueous humour. However, patients with severe uveitis had significant levels of CsA in the aqueous humour and in the vitreous. No CsA was found in the cerebrospinal fluid of two patients with central nervous system manifestations of Behçet's disease. After local treatment with 2% CsA eye drops no detectable levels of CsA were found in the blood, the saliva, the aqueous humour, or the vitreous even in patients with severe uveitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2378841      PMCID: PMC1042125          DOI: 10.1136/bjo.74.6.350

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  14 in total

1.  Treatment and visual prognosis in Behçet's disease.

Authors:  D Benezra; E Cohen
Journal:  Br J Ophthalmol       Date:  1986-08       Impact factor: 4.638

2.  Cyclosporin A in the treatment of posterior uveitis.

Authors:  E M Graham; M D Sanders; D G James; A Hamblin; E Kasp Grochowska; D Dumonde
Journal:  Trans Ophthalmol Soc U K       Date:  1985

3.  Cyclosporine penetration into the anterior chamber and cerebrospinal fluid.

Authors:  A G Palestine; R B Nussenblatt; C C Chan
Journal:  Am J Ophthalmol       Date:  1985-02-15       Impact factor: 5.258

4.  Renal interstitial fibrosis and vascular changes. Occurrence in patients with autoimmune diseases treated with cyclosporine.

Authors:  K Svenson; S O Bohman; R Hällgren
Journal:  Arch Intern Med       Date:  1986-10

5.  Cyclosporin A: tissue levels following topical and systemic administration to rabbits.

Authors:  T A Bell; A G Hunnisett
Journal:  Br J Ophthalmol       Date:  1986-11       Impact factor: 4.638

6.  Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents.

Authors:  R B Nussenblatt; A G Palestine; C C Chan
Journal:  Am J Ophthalmol       Date:  1983-09       Impact factor: 5.258

7.  Modulation of experimental autoimmune uveitis with cyclosporin A.

Authors:  R B Nussenblatt; M M Rodrigues; M C Salinas-Carmona; I Gery; S Cevario; W Wacker
Journal:  Arch Ophthalmol       Date:  1982-07

8.  The use of cyclosporin A in clinical organ grafting.

Authors:  R Y Calne; D J White
Journal:  Ann Surg       Date:  1982-09       Impact factor: 12.969

9.  Renal histopathologic alterations in patients treated with cyclosporine for uveitis.

Authors:  A G Palestine; H A Austin; J E Balow; T T Antonovych; S G Sabnis; H G Preuss; R B Nussenblatt
Journal:  N Engl J Med       Date:  1986-05-15       Impact factor: 91.245

10.  Pharmacokinetic of topical cyclosporin A in the rabbit eye.

Authors:  M Wiederholt; D Kössendrup; W Schulz; F Hoffmann
Journal:  Invest Ophthalmol Vis Sci       Date:  1986-04       Impact factor: 4.799

View more
  17 in total

Review 1.  New developments in sustained release drug delivery for the treatment of intraocular disease.

Authors:  G Velez; S M Whitcup
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Systemic ciclosporin A in high-risk keratoplasties.

Authors:  T Reinhard; R Sundmacher; P Heering
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-08       Impact factor: 3.117

Review 3.  [Pharmacokinetics of systemic, regional and topical drugs for therapy of intraocular inflammation].

Authors:  M D Becker; S Lortz; B Flückiger; V Luginbuehl
Journal:  Ophthalmologe       Date:  2014-02       Impact factor: 1.059

4.  Diclofenac sodium and cyclosporin A inhibit human lens epithelial cell proliferation in culture.

Authors:  P Cortina; M J Gómez-Lechón; A Navea; J L Menezo; M C Terencio; M Diaz-Llopis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-03       Impact factor: 3.117

5.  Long-term therapy with low dose cyclosporin A in ocular Behçet's disease.

Authors:  Pinar Cakar Ozdal; Serap Ortaç; Ibrahim Taskintuna; Esin Firat
Journal:  Doc Ophthalmol       Date:  2002-11       Impact factor: 2.379

6.  Cyclosporin A in the ocular fluids of uveitis patients following long-term systemic administration.

Authors:  Paolo Mora; Uta Ceglarek; Francesca Manzotti; Laura Zavota; Arturo Carta; Raffaella Aldigeri; Jelka G Orsoni
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-05-06       Impact factor: 3.117

7.  A compartmental model for the ocular pharmacokinetics of cyclosporine in rabbits.

Authors:  C Oh; B A Saville; Y L Cheng; D S Rootman
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

Review 8.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  Application of sustained delivery microsphere of cyclosporine A for preventing posterior capsular opacification in rabbits.

Authors:  Cheng Pei; Yi Xu; Jean Xin Jiang; Li-Jun Cui; Li Li; Li Qin
Journal:  Int J Ophthalmol       Date:  2013-02-18       Impact factor: 1.779

10.  Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6.

Authors:  Hyoung J Koh; Kenichiro Bessho; Lingyun Cheng; Dirk-Uwe Bartsch; Terence R Jones; Germain Bergeron-Lynn; William R Freeman
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-02       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.